Xin Lang Cai Jing·2025-12-05 07:29Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2] Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibodies and therapeutic proteins [7] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2] - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the EU, the US, and Australia [2] - Junshi's Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III trials and several combination studies with Toripalimab [2] Collaborations and Vaccine Development - On October 27, 2023, Junshi announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3] - The company's subsidiary, JunTuo Biotech, is also involved in the development of vaccines for monkeypox and Zika, currently in the preclinical stage [3] Financial Performance - For the period from January to September 2025, Junshi reported revenues of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a 35.72% increase year-on-year [8] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, with an average of 21,361 shares per shareholder, a decrease of 12.96% [8] Market Position - Junshi Biosciences operates within the pharmaceutical and biotechnology sector, focusing on innovative drugs, monkeypox concepts, and precision medicine [8] - The stock has seen a recent trading volume of 155 million yuan with a market capitalization of 36.961 billion yuan [1]